製品の概要

  • 製品名Anti-SLC6A20 antibody
  • 製品の詳細
    Mouse monoclonal to SLC6A20
  • アプリケーション適用あり: WBmore details
  • 種交差性
    交差種: Human
  • 免疫原

    Recombinant fragment: KATFNYENCL KKVSLLLTNT FDLEDGFLTA SNLEQVKGYL ASAYPSKYSE MFPQIKNCSL ESELDTAVQ, corresponding to amino acids 301-370 of Human SLC6A20

製品の特性

  • 製品の状態Liquid
  • 保存方法Shipped at 4°C. Upon delivery aliquot and store at -20°C or -80°C. Avoid repeated freeze / thaw cycles.
  • バッファーPreservative: None
    PBS, pH 7.2
  • Concentration information loading...
  • 精製度Protein G purified
  • ポリ/モノモノクローナル
  • アイソタイプIgG1
  • 軽鎖の種類kappa
  • 研究分野

アプリケーション

Our Abpromise guarantee covers the use of ab57408 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

アプリケーション Abreviews 特記事項
WB
  • 追加情報WB: Use at a concentration of 1-5 µg/ml.

    This antibody has only been tested in WB against the recombinant fragment used as immunogen. We have no data on the detection of endogenous protein.

    Not yet tested in other applications.
    Optimal dilutions/concentrations should be determined by the end user.
  • ターゲット情報

    • 機能Mediates the calcium-dependent uptake of imino acids such as L-proline, N-methyl-L-proline and pipecolate as well as N-methylated amino acids. Involved in the transport of glycine.
    • 組織特異性Kidney and small intestine. Expressed in the S3 segment of the proximal tubule.
    • 関連疾患Defects in SLC6A20 are a cause of hyperglycinuria (HG) [MIM:138500]. It is a condition characterized by excess of glycine in the urine. In some cases it is associated with renal colic and renal oxalate stones.
      Defects in SLC6A20 are a cause of iminoglycinuria (IG) [MIM:242600]. It is a disorder of renal tubular reabsorption of glycine and imino acids (proline and hydroxyproline), marked by excessive levels of all three substances in the urine. Note=Haploinsufficiency of SLC6A20 combined with deficiency of the neutral amino acid transporter SLC6A19 or partially inactivating mutations in SLC36A2, is responsible for iminoglycinuria. Additional polymorphisms and mutations in SLC6A18 can contribute to the IG phenotype in some families.
    • 配列類似性Belongs to the sodium:neurotransmitter symporter (SNF) (TC 2.A.22) family. SLC6A20 subfamily.
    • 細胞内局在Apical cell membrane. Located in the apical brush border membrane of kidney proximal tubule cells.
    • Information by UniProt
    • 参照データベース
    • 別名
      • MGC161475 antibody
      • Neurotransmitter transporter RB21A antibody
      • Neurotransmitter transporter rB21A homolog antibody
      • Orphan transporter XT3 antibody
      • S6A20_HUMAN antibody
      • SIT 1 antibody
      • SIT1 antibody
      • SLC6A20 antibody
      • Sodium and chloride dependent transporter XTRP3 antibody
      • Sodium- and chloride-dependent transporter XTRP3 antibody
      • Sodium/imino acid transporter 1 antibody
      • Sodium/imino-acid transporter 1 antibody
      • Solute carrier family 6 (neurotransmitter transporter) member 20 antibody
      • Solute carrier family 6 (proline IMINO transporter) member 20 antibody
      • Solute carrier family 6 member 20 antibody
      • Transporter rB21A homolog antibody
      • X transporter protein 3 antibody
      • XT 3 antibody
      • XT3 antibody
      • Xtrp 3 antibody
      • Xtrp3 antibody
      see all

    Anti-SLC6A20 antibody 画像

    • Western blot against tagged recombinant protein immunogen using ab57408 SLC6A20 antibody at 1ug/ml. Predicted band size of immunogen is 37 kDa

    Anti-SLC6A20 antibody (ab57408) 使用論文

    ab57408 has not yet been referenced specifically in any publications.

    Product Wall

    Thank you for contacting Abcam regarding compatible secondary antibodies. For the rabbit antibodies (ab96394, ab18305, and ab98046) I would recommend the secondary antibody ab6721, Goat polyclonal Secondary Antibody to Rabbit IgG - H&L (HRP). For...

    Read More

    Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"